Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma.

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Abstract Text:

Tim F Cloughesy,Koji Yoshimoto,Phioanh Nghiemphu,Kevin Brown,Julie Dang,Shaojun Zhu,Teli Hsueh,Yinan Chen,Wei Wang,David Youngkin,Linda Liau,Neil Martin,Don Becker,Marvin Bergsneider,Albert Lai,Richard Green,Tom Oglesby,Michael Koleto,Jeff Trent,Steve Horvath,Paul S Mischel,Ingo K Mellinghoff,Charles L Sawyers,Tim F Cloughesy,Koji Yoshimoto,Phioanh Nghiemphu,Kevin Brown,Julie Dang,Shaojun Zhu,Teli Hsueh,Yinan Chen,Wei Wang,David Youngkin,Linda Liau,Neil Martin,Don Becker,Marvin Bergsneider,Albert Lai,Richard Green,Tom Oglesby,Michael Koleto,Jeff Trent,Steve Horvath,Paul S Mischel,Ingo K Mellinghoff,Charles L Sawyers,

BACKGROUND: There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patients who are more likely to benefit. Small, molecularly focused clinical studies offer the promise of the early definition of optimal biologic dose and patient population. METHODS AND FINDINGS: Based on preclinical evidence that phosphatase and tensin homolog deleted on Chromosome 10 (PTEN) loss sensitizes tumors to the inhibition of mammalian target of rapamycin (mTOR), we conducted a proof-of-concept Phase I neoadjuvant trial of rapamycin in patients with recurrent glioblastoma, whose tumors lacked expression of the tumor suppressor PTEN. We aimed to assess the safety profile of daily rapamycin in patients with glioma, define the dose of rapamycin required for mTOR inhibition in tumor tissue, and evaluate the antiproliferative activity of rapamycin in PTEN-deficient glioblastoma. Although intratumoral rapamycin concentrations that were sufficient to inhibit mTOR in vitro were achieved in all patients, the magnitude of mTOR inhibition in tumor cells (measured by reduced ribosomal S6 protein phosphorylation) varied substantially. Tumor cell proliferation (measured by Ki-67 staining) was dramatically reduced in seven of 14 patients after 1 wk of rapamycin treatment and was associated with the magnitude of mTOR inhibition (p = 0.0047, Fisher exact test) but not the intratumoral rapamycin concentration. Tumor cells harvested from the Ki-67 nonresponders retained sensitivity to rapamycin ex vivo, indicating that clinical resistance to biochemical mTOR inhibition was not cell-intrinsic. Rapamycin treatment led to Akt activation in seven patients, presumably due to loss of negative feedback, and this activation was associated with shorter time-to-progression during post-surgical maintenance rapamycin therapy (p < 0.05, Logrank test). CONCLUSIONS: Rapamycin has anticancer activity in PTEN-deficient glioblastoma and warrants further clinical study alone or in combination with PI3K pathway inhibitors. The short-term treatment endpoints used in this neoadjuvant trial design identified the importance of monitoring target inhibition and negative feedback to guide future clinical development.Trial registration: http://www.ClinicalTrials.gov (#NCT00047073).

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Publishing Authors By Initials

TF Cloughesy,K Yoshimoto,P Nghiemphu,K Brown,J Dang,S Zhu,T Hsueh,Y Chen,W Wang,D Youngkin,L Liau,N Martin,D Becker,M Bergsneider,A Lai,R Green,T Oglesby,M Koleto,J Trent,S Horvath,PS Mischel,IK Mellinghoff,CL Sawyers,TF Cloughesy,K Yoshimoto,P Nghiemphu,K Brown,J Dang,S Zhu,T Hsueh,Y Chen,W Wang,D Youngkin,L Liau,N Martin,D Becker,M Bergsneider,A Lai,R Green,T Oglesby,M Koleto,J Trent,S Horvath,PS Mischel,IK Mellinghoff,CL Sawyers,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: PLoS medicine

VOLUME: 5

Page Numbers: e8

Journal Abbreviation: PLoS Med.

ISSN: 1549-1676

DAY: 22

MONTH: Jan

YEAR: 2008

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101231360

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: PLoS Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma Related Publications

• Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma.
• Cancer: mixing cocktails.
• Something lost - something gained: the ASCI begins its second century.
• Steroid-induced striae in severe nephrotic syndrome.
• The cancer biomarker problem.
• Treating imatinib-resistant leukemia: the next generation targeted therapies.
• Where lies the blame for resistance--tumor or host?